Skip to content
PEPTIDESUNCENSORED

CJC-1295

/C · J · C twelve-ninety-five/aka CJC-1295 with DAC, CJC-1295 no DAC, Mod GRF 1-29

A modified GHRH(1-29) fragment that triggers pituitary GH release, sold as a week-long albumin-binding version (with DAC) and a short-acting one (no DAC).

SubcutaneousDaily2×/dayWeekly
Open in cycle visualizer

CJC-1295: educational research discussion. Not medical advice. Not a protocol for you.Details

Reported range
100–300 mcg (no DAC)
Frequency
1–3× daily (no DAC); weekly (DAC)
Cycle length
8–12 week blocks, then a break
Half-life
≈ 6–8 days (DAC); short (no DAC)
Route
SC

Reported figures describe what is published or discussed. None of them is a dose for you.

Mechanism

What it is proposed to do

Both forms are GHRH(1-29) with four amino-acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist enzymatic breakdown; the no-DAC form is usually called Mod GRF 1-29. They bind pituitary GHRH receptors and increase the body's own GH release, which raises IGF-1. The DAC version adds a reactive linker that bonds covalently to circulating albumin, stretching the half-life to about a week. In a 2006 study, natural GH pulses continued on top of a much higher baseline, so the DAC form adds a constant signal rather than a brief pulse.

  1. 01

    CJC-1295

    DAC: ~6–8 day half-life via albumin. No DAC: short-acting

    established
  2. 02

    Pituitary GHRH receptor

    Same receptor as your own GHRH

    established
  3. 03

    GH ↑ · IGF-1 ↑

    Measured in healthy adults for the DAC version (2006)

    established
  4. 04

    Body composition, recovery

    Extrapolated from GH physiology; never tested for CJC-1295

    proposed
EstablishedProposed from animal or cell data

Half-life. With DAC: 5.8–8.1 days in healthy adults (2006). Without DAC: commonly cited as about 30 minutes, but published human pharmacokinetic data are lacking.

Dosing & cycles

What is reported, and where it comes from

Numbers below are labeled FDA label, clinical trial range or commonly reported range. They describe the published and discussed landscape. They are not instructions and not a protocol for you.

Dosing studio

Every figure is labeled by where it comes from.

This is not your dose

Scale view: Commonly reported range, no DAC

0
100
200
300
400
500

Probe at 200 mcg: inside the reported band (100–300 mcg). Drag it to read the scale. It does not pick a number for you.

Typical cycle, as a calendar

No DAC + ipamorelin: 5 on / 2 off

8–12 week blocks

The classic community pattern: short-acting CJC-1295 paired with ipamorelin on weekdays, weekends off, then a break. Block and break lengths are convention, not data.

OffLow / startMid / loadingHigh / maintenance

Cycle patterns

No DAC + ipamorelin: 5 on / 2 off

8–12 week blocks

The classic community pattern: short-acting CJC-1295 paired with ipamorelin on weekdays, weekends off, then a break. Block and break lengths are convention, not data.

5 on / 2 off
Break
Week 1Week 16

With DAC: once weekly

8–12 weeks, then a break

One injection a week, leaning on the albumin-bound half-life. The 2006 studies ran for 28 and 49 days; we found no longer published human data.

Weekly
Break
Week 1Week 14

Stacks

What it gets combined with

Why people pair things, and what nobody has tested.

CJC-1295 (no DAC) + ipamorelin

2 compounds
CJC-1295Ipamorelin
Why people combine these
The classic pair. A GHRH analog sets the size of the GH pulse; a ghrelin-receptor agonist triggers release and blunts somatostatin, the brake. Older human studies (GHRP-6 with GHRH) showed the two classes act synergistically.
Caution
No trial has tested this specific pair. More GH signal means more fluid retention and glucose effects, and vials labeled "CJC-1295" may contain either form.
What is unknown
No published human data on this combination: dosing, interactions and long-term effects are all unstudied.

GH-axis + repair

3 compounds
CJC-1295BPC-157TB-500
Why people combine these
Some add GH-axis peptides to repair peptides for a proposed effect on collagen synthesis and recovery.
Caution
Layers growth signaling on top of compounds with no human efficacy data. With any cancer history, this belongs in a conversation with an oncologist, not a forum.
What is unknown
No published human data on this combination: dosing, interactions and long-term effects are all unstudied.

Also sold in pre-mixed blends

What a blend changes

In a blend, CJC-1295 cannot be adjusted on its own, and the mixture has no human data of its own. Typical vial formats shown; labels vary.

Evidence

How much of this is known

Evidence grade

C

Thin human data

Human data thin (pilots, uncontrolled, or none completed). Strong animal data and a lot of anecdote.

How we grade

Small human pharmacokinetic and hormone studies of the DAC version only. No efficacy trials, no approval, and almost nothing on the no-DAC form most people discuss.

Human trial status

Two randomized, placebo-controlled, ascending-dose trials in healthy adults (published 2006) found a half-life of 5.8–8.1 days for the DAC version. Single injections raised GH 2–10-fold for 6 or more days and IGF-1 1.5–3-fold for 9–11 days. A second 2006 study found GH pulses persisted while trough GH rose 7.5-fold. A Phase 2 trial in HIV-associated visceral fat was halted in July 2006 after a participant died, and no efficacy results were published.

Limitations

  • All published human data are hormone measurements, not clinical outcomes.
  • The no-DAC form has almost no published human data, yet it is the form most discussed.
  • FDA staff told advisers in 2024 that CJC-1295 materials are poorly characterized, partly because of inconsistent naming.
  • Body composition, sleep and recovery claims are extrapolated from GH physiology.

Sources to read

Links open PubMed, DailyMed, FDA or trial-registry searches. We do not cite what we have not described accurately.

Safety

Side effects, cautions, status

Commonly reported effects

  • The 2006 studies reported no serious adverse reactions; tolerability was best at the lower doses tested.
  • Commonly reported: flushing, injection-site redness, water retention, and tingling or numbness in the hands.
  • Raised GH can reduce insulin sensitivity, as seen with GH therapy and on the tesamorelin label.
  • Hunger is reported less often than with ghrelin-receptor agonists such as GHRP-6, since GHRH analogs do not act on that receptor.
  • A 2006 Phase 2 trial was stopped after a participant died. The company reported the death as most likely unrelated, and development never resumed.
Water retentionFlushingInjection-site reactionsNumbness / tinglingBlood glucose changes

Who should be extra cautious

  • Active or past cancer. The DAC form keeps GH and IGF-1 raised for days per injection. IGF-1 is a growth signal; there is no human safety data in this group.
  • Diabetes or prediabetes. GH elevation can worsen insulin sensitivity.
  • Pregnancy or breastfeeding. No data.
  • Tested athletes. Prohibited at all times (WADA S2.2.4, named).
  • Gray-market product. Labels often do not state which form is in the vial. FDA advisers called CJC-1295 materials poorly characterized.

Legal & regulatory status

Not approved anywhere. Developer ConjuChem stopped development after a Phase 2 trial was halted in 2006. In December 2024 an FDA advisory committee voted 0–13 against adding CJC-1295 to the 503A bulks list, and it has not been added since.

2026 compounding context. CJC-1295 was not among the peptides in FDA's April 2026 Category 2 changes or the July 2026 advisory committee review. The December 2024 vote is the most recent formal review we found. FDA staff described CJC-1295 materials as not well characterized, citing inconsistent naming and missing characterization data.

WADA. Prohibited at all times as a GHRH analogue (S2.2.4). CJC-1295 is named on the list; the no-DAC form is covered as a GHRH analogue.

Storage & handling, high level

Sold as lyophilized powder. Reconstituted peptides are generally kept refrigerated, away from light, and degrade over weeks. Whether a vial holds the DAC or no-DAC form matters more than any storage detail.

Reconstitution and injection technique are clinical skills. The reconstitution calculator does arithmetic only.

FAQ

Questions people ask about CJC-1295

What is the difference between DAC and no DAC?
DAC (drug affinity complex) is a chemical linker that lets the peptide bond to albumin in the blood. That stretches the half-life to about 6–8 days and keeps GH raised all week. Without DAC, the same modified GHRH fragment (Mod GRF 1-29) clears quickly and gives a short pulse after each injection. Same receptor, very different exposure.
Which one is the "real" CJC-1295?
The name originally belonged to the DAC version, the one ConjuChem tested in people. Vendors later applied it to Mod GRF 1-29 as "CJC-1295 no DAC". FDA staff cited this naming mess in 2024. A vial that does not specify the form is ambiguous by definition.
Why is it paired with ipamorelin?
They act on different receptors in the same system. A GHRH analog amplifies the GH pulse; a ghrelin-receptor agonist triggers it. Human studies with older compounds show the two classes are synergistic. Nobody has run a trial of this specific pair.
Did someone die in a CJC-1295 trial?
Yes. In July 2006 ConjuChem halted a Phase 2 trial in HIV-associated visceral fat after a participant died. The company later reported the treating physician judged the death most likely due to undiagnosed coronary artery disease and unrelated to the drug. Development never resumed.

The monthly Evidence Brief

Keep up with the evidence

One email a month: new trials, grade changes and FDA or WADA updates across the whole atlas, CJC-1295 included. You get the free guide right away.

Cover of the free guide, 10 Peptide Claims, Fact-Checked

Free guide · PDF

10 Peptide Claims, Fact-Checked

13 pages · sent to your inbox right away

Email only. Unsubscribe from any email in one click. We do not sell or rent your address. Nothing we send is medical advice. Privacy